Regulation of Glycolysis in Head and Neck Cancer

Adv Exp Med Biol. 2021:1280:219-230. doi: 10.1007/978-3-030-51652-9_15.

Abstract

Head and neck squamous cell carcinoma (HNSCC) glycolysis is an important factor for the advancement of the disease and metastasis. Upregulation of glycolysis leads to decreased sensitivity to chemotherapy and radiation. HNSCC cells maintain constitutive glycolytic flux generating metabolic intermediates for the synthesis of amino acids, nucleotides, and fats for cell survival and disease progression. There are several pathways such as PI3K/Akt, EGFR, and JAK-STAT that contribute a major role in metabolic alteration in HNSCC. Recent studies have demonstrated that cancer-associated fibroblasts abundant in the HNSCC tumor microenvironment play a major role in HNSCC metabolic alteration via hepatocyte growth factor (HGF)/c-Met cross signaling. Despite therapeutic advancement, HNSCC lacks broad range of therapeutic interventions for the treatment of the disease. Thus, understanding the different key players involved in glucose metabolism and targeting them would lead to the development of novel drugs for the treatment of HNSCC.

Keywords: Akt; GLUT-1; Glycolysis; HGF/c-MET; HK-II; HNSCC; LDH-A; MCT; PI3K; TAFs.

MeSH terms

  • Carcinoma, Squamous Cell* / drug therapy
  • Cell Line, Tumor
  • Glycolysis
  • Head and Neck Neoplasms* / drug therapy
  • Humans
  • Phosphatidylinositol 3-Kinases / genetics
  • Tumor Microenvironment